Trails Edge Capital Partners
Trails Edge Capital Partners reported 38 stocks worth $696M in its 13F filing for Q3 2026, filed Nov 16, 2026. Its largest holdings are LBRX (6.3%), BMRN (5.8%) and NRIX (5.4%). Compared with Q2 2026, the fund opened new positions in OBX, TNGX and CLDX, added to BMRN, DSGN and CYTK, trimmed LBRX, TRAX and XENE and sold out of MIRM, INSM and SNDX.
Latest filing: what Trails Edge Capital Partners did in Q3 2026
vs Q2 2026Dollar changes use the share change at the quarter end price. New and sold out show the whole position.
Portfolio at a glance
share of reported value · Q3 2026Holdings
| # | Stock | Value | Weight | Shares | Change | Shares, 4 qtrs | Held |
|---|---|---|---|---|---|---|---|
| 1 | ![]() LBRX LB Pharmaceuticals Inc | $44.1M | 6.3% | 1.1M | −374K (−25%) | 4 of 4 | |
| 2 | ![]() BMRN Biomarin Pharmaceutical Inc | $40M | 5.8% | 667K | +155K (+30%) | 2 of 4 | |
| 3 | ![]() NRIX Nurix Therapeutics Inc | $37.3M | 5.4% | 1.6M | No change | 4 of 4 | |
| 4 | ![]() OBX Obsidian Therapeutics Inc | $34.3M | 4.9% | 2.5M | New position | 1 of 4 | |
| 5 | ![]() IMCR Immunocore Hldgs PLC | $32.2M | 4.6% | 1.1M | No change | 4 of 4 | |
| 6 | ![]() FDMT 4D Molecular Therapeutics in | $31.9M | 4.6% | 2.2M | No change | 3 of 4 | |
| 7 | ![]() DSGN Design Therapeutics Inc | $31.4M | 4.5% | 2.5M | +499K (+25%) | 3 of 4 | |
| 8 | ![]() CYTK Cytokinetics Inc | $31M | 4.5% | 470K | +182K (+63%) | 3 of 4 | |
| 9 | ![]() TRAX First Tracks Biotherapeutics | $28.8M | 4.2% | 814K | −700K (−46%) | 2 of 4 | |
| 10 | ![]() FTH Sensei Biotherapeutics Inc | $28M | 4.0% | 942K | +426K (+83%) | 3 of 4 |
Positions at Sep 30, 2026, as reported. Change is against the fund's Q2 2026 filing; weight is the share of the fund's reported stocks.
Sold out
held in Q2 2026, gone in Q3 2026| Stock | Value last quarter | Shares sold |
|---|---|---|
![]() MIRM Mirum Pharmaceuticals Inc | $26.1M | 223K |
![]() INSM Insmed Inc | $24.6M | 230K |
![]() SNDX Syndax Pharmaceuticals Inc | $24.3M | 1.1M |
![]() RVMD Revolution Medicines Inc | $21.7M | 116K |
![]() INCY Incyte Corp | $17.6M | 155K |
🔒 Free account: see all 6.
Reported value
last 4 quartersThe value of the US stocks the fund reported, at quarter end prices. It moves with the market as well as with buying and selling.
Filings for Q3 2026
straight from the SEC| Filed | Form | Quarter | |
|---|---|---|---|
| Nov 16, 2026 | 13F-HR | Q3 2026 | SEC filing ↗ |
Other superinvestors
All hedge fund holdings →Trails Edge Capital Partners 13F FAQ
What does Trails Edge Capital Partners own?
Trails Edge Capital Partners reported 38 stocks worth $696M in its 13F filing for Q3 2026, filed Nov 16, 2026. Its largest holdings are LBRX (6.3%), BMRN (5.8%) and NRIX (5.4%). The table above lists every position in the filing (the top 10 without an account).
What did Trails Edge Capital Partners buy and sell in Q3 2026?
Compared with Q2 2026: 9 new positions, 12 added to, 7 trimmed and 6 sold out. New positions include OBX, TNGX and CLDX. It sold all of MIRM, INSM and SNDX.
When will Trails Edge Capital Partners file its next 13F?
Holdings as of Dec 31, 2026 are due by Feb 15, 2027. The filing appears on this page within minutes of reaching the SEC.
How much is Trails Edge Capital Partners's portfolio worth?
The Q3 2026 filing reports $696M in US stocks. That leaves out cash, bonds, short positions and most foreign holdings, so the fund's total assets are usually larger.
For informational and educational purposes only. Not investment advice, and not a recommendation to buy or sell any security. Holdings come from the fund's SEC Form 13F filings as reported and show positions at the end of the quarter, up to 45 days before the filing. The fund may have changed its positions since. A 13F leaves out short positions, cash, bonds and most foreign holdings. See all hedge fund holdings.























